Cases & Deals

Celgene asserts its REVLIMID® patents against Cipla under Hatch-Waxman Act

Clients Celgene Corporation

Jones Day is representing Celgene Corporation as a plaintiff to enforce its patents against Cipla Limited in Hatch-Waxman litigation matters involving Cipla’s proposed generic versions of REVLIMID®, which is prescribed for treating multiple myeloma and other cancers.

Celgene Corporation v. Cipla Limited, No. 2-17-cv-06163, 2-18-cv-08964 (D.N.J.)

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.